New WHO ACPA standard enables standardisation among anti-CCP2 assays, but not other ACPA assays usin...
New WHO ACPA standard enables standardisation among anti-CCP2 assays, but not other ACPA assays using different antigens
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd and European League Against Rheumatism
Subjects
More information
Scope and Contents
Contents
Antibodies to citrullinated protein/peptide (ACPA) are established biomarkers for diagnosis and classification of rheumatoid arthritis (RA).1 Different generations of ACPA immunoassays are commercially available, with differences in antigen used (eg, citrullinated recombinant rat filaggrin (CCP1), synthetic cyclic citrullinated peptides (CCP2), mul...
Alternative Titles
Full title
New WHO ACPA standard enables standardisation among anti-CCP2 assays, but not other ACPA assays using different antigens
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3083663391
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3083663391
Other Identifiers
ISSN
0003-4967,1468-2060
E-ISSN
1468-2060
DOI
10.1136/ard-2024-226169
